{"id":7090,"date":"2021-06-28T08:10:34","date_gmt":"2021-06-28T08:10:34","guid":{"rendered":"https:\/\/ncrfrontlinenews.com\/?p=7090"},"modified":"2021-06-28T08:10:34","modified_gmt":"2021-06-28T08:10:34","slug":"eu-travel-issues-taken-this-up-at-highest-level-says-adar-poonawalla-on-covidshield","status":"publish","type":"post","link":"https:\/\/ncrfrontlinenews.com\/?p=7090","title":{"rendered":"EU Travel Issues: Taken this up at highest level, says Adar Poonawalla on Covidshield"},"content":{"rendered":"<p>New Delhi: Serum Institute of India\u2019s Adar Poonawalla on Monday said he has spoken with authorities after the AstraZeneca-Oxford vaccine, which is being manufactured by his company, was excluded from the list of anti-Covid-19 shots that are eligible for the European Union\u2019s \u201cGreen Pass\u201d.<\/p>\n<p>\u201cI realise that a lot of Indians who have taken COVISHIELD are facing issues with travel to the E.U., I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries,\u201d Adar Poonawalla tweeted.<\/p>\n<p>This comes after reports that travellers vaccinated with Covishield, the AstraZeneca-Oxford vaccine manufactured in India by the SII, may not be eligible for the European Union\u2019s \u2018Green Pass\u2019.<\/p>\n<p>Europe\u2019s vaccine passport programme, which allowed recipients to travel to and from Europe with fewer roadblocks, may not recognise recipients of the Covishield vaccine.<\/p>\n<p>Covishield is one of the three COVID-19 vaccines approved for use in India.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Delhi: Serum Institute of India\u2019s Adar Poonawalla on Monday said he has spoken with authorities after the AstraZeneca-Oxford vaccine, which is being manufactured by his company, was excluded from the list of anti-Covid-19 shots that are eligible for the European Union\u2019s \u201cGreen Pass\u201d. \u201cI realise that a lot of Indians who have taken COVISHIELD [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7091,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"post-7090","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"_links":{"self":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/7090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7090"}],"version-history":[{"count":1,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/7090\/revisions"}],"predecessor-version":[{"id":7092,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/7090\/revisions\/7092"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/media\/7091"}],"wp:attachment":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}